View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 27, 2016

Adimmune continues patient enrolment for Phase III trial of Quadrivalent Influenza Vaccine

Asian flu vaccine provider Adimmune is continuing with patient enrolment for its Phase III trial of Quadrivalent Influenza Vaccine in Europe.

Asian flu vaccine provider Adimmune is continuing with patient enrolment for its Phase III trial of Quadrivalent Influenza Vaccine in Europe.

The quadrivalent flu vaccines are designed to protect against four different flu viruses: two influenza A and two influenza B.

With the number of patients recruited crossing 1,000, the Phase III trial is the largest clinical trial held in Europe, initiated by a Taiwanese vaccine company and is considered as a milestone for Adimmune to begin selling its own-brand product in Europe.

"The quadrivalent flu vaccines are designed to protect against four different flu viruses: two influenza A and two influenza B."

Enrolment for the study is expected to close by the end of this year.

Meanwhile, strategic collaboration between Adimmune and Techdow Pharmaceutical has obtained approval to manufacture Enoxaparin Sodium pre-filled syringes in Poland and other sites within the European Union (EU).

The collaboration was initiated in 2013, under which Techdow provided Enoxaparin API, while Adimmune provides a pre-filled syringe filling service and ships to Europe.

Europe has strong demand for enoxaparin sodium and Adimmune expects the usage rate of its PFS production line to quickly increase after mass production.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena